PhilHealth TB medicines coverage will expand on November 1, 2026, giving eligible members and dependents another way to obtain selected first-line tuberculosis treatments. The Philippine Health Insurance Corporation said the medicines will be available through accredited GAMOT facilities without reducing members’ ₱20,000 annual allowance for other covered outpatient medicines.
Key Takeaways
- The expansion covers eligible patients with confirmed drug-susceptible tuberculosis.
- Covered anti-TB medicines will not count toward the annual ₱20,000 GAMOT limit.
- The additional access route complements, rather than replaces, PhilHealth’s existing outpatient TB care package.
Table of Contents
- Who can access PhilHealth TB medicines?
- Prescription and collection requirements
- How the expansion fits existing TB coverage
- Conclusion
Who can access PhilHealth TB medicines?
Under PhilHealth Circular 2026-0018, eligible patients with confirmed drug-susceptible tuberculosis may obtain covered medicines at PhilHealth-accredited Guaranteed and Accessible Medications for Outpatient Treatment, or GAMOT, facilities.
PhilHealth’s expanded anti-TB medicine benefit requires prescriptions from physicians accredited under the Yaman ng Kalusugan Program, known as YAKAP. Those physicians must issue prescriptions through the GAMOT application and follow Department of Health–National TB Control Program treatment protocols.
The financial distinction is important: covered anti-TB medicines sit outside the annual GAMOT benefit limit. Members therefore retain that allocation for other covered outpatient medicines, rather than having TB prescriptions draw down the same allowance.
| Item | Details |
|---|---|
| Implementation date | November 1, 2026. |
| Policy authority | PhilHealth Circular 2026-0018. |
| Maximum prescription supply | Up to one month per transaction. |
| Dispensing deadline | Complete prescribed quantity within two days of prescription issuance. |
Prescription and collection requirements
Physicians may prescribe up to a one-month supply of first-line anti-TB medicines per transaction. The accredited GAMOT facility must dispense the complete prescribed quantity within two days of the prescription’s issuance.
Patients must claim medicines within the prescribed period. PhilHealth said those who miss that period may still obtain the medicines but must either pay out of pocket or secure an updated prescription.
Before dispensing anti-TB medicines, participating facilities must submit an updated Certification of Availability to their PhilHealth Regional Office. PhilHealth will reimburse facilities directly using the fixed-fee schedule specified in the circular.
How the expansion fits existing TB coverage
The Outpatient TB-DOTS Package remains PhilHealth’s primary benefit for comprehensive outpatient tuberculosis care. TB-DOTS facilities will continue providing care and dispensing medicines when their supplies are available and sufficient.
If first-line anti-TB drugs are dispensed through a GAMOT facility instead, an automatic 50% deduction will apply to the TB-DOTS package claim for each treatment phase. This is an adjustment to the package claim, separate from the protection of the member’s annual GAMOT allowance.
PhilHealth encouraged members to consult their YAKAP-authorized physician or TB-DOTS provider about treatment arrangements and access to the expanded benefit.
Conclusion
The next confirmed milestone is the November 1, 2026 rollout. PhilHealth TB medicines access will then broaden through participating GAMOT facilities, subject to eligibility, prescription and collection requirements.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
